KR20050074450A - 골수형성이상 증후군의 치료용 약물의 제조를 위한4-피리딜메틸-프탈라진 유도체의 용도 - Google Patents

골수형성이상 증후군의 치료용 약물의 제조를 위한4-피리딜메틸-프탈라진 유도체의 용도 Download PDF

Info

Publication number
KR20050074450A
KR20050074450A KR1020057004971A KR20057004971A KR20050074450A KR 20050074450 A KR20050074450 A KR 20050074450A KR 1020057004971 A KR1020057004971 A KR 1020057004971A KR 20057004971 A KR20057004971 A KR 20057004971A KR 20050074450 A KR20050074450 A KR 20050074450A
Authority
KR
South Korea
Prior art keywords
pyridylmethyl
formula
vitamin
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057004971A
Other languages
English (en)
Korean (ko)
Inventor
마가렛 한 더건
앨런 리스트
Original Assignee
노파르티스 아게
디 애리조나 보드 오브 리젠츠 온 비해프 오브 더 유니버시티 오브 애리조나
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 디 애리조나 보드 오브 리젠츠 온 비해프 오브 더 유니버시티 오브 애리조나 filed Critical 노파르티스 아게
Publication of KR20050074450A publication Critical patent/KR20050074450A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020057004971A 2002-09-24 2003-09-23 골수형성이상 증후군의 치료용 약물의 제조를 위한4-피리딜메틸-프탈라진 유도체의 용도 Ceased KR20050074450A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
US60/413,176 2002-09-24

Publications (1)

Publication Number Publication Date
KR20050074450A true KR20050074450A (ko) 2005-07-18

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057004971A Ceased KR20050074450A (ko) 2002-09-24 2003-09-23 골수형성이상 증후군의 치료용 약물의 제조를 위한4-피리딜메틸-프탈라진 유도체의 용도

Country Status (22)

Country Link
US (1) US20060128716A1 (https=)
EP (1) EP1545534B1 (https=)
JP (1) JP2006502195A (https=)
KR (1) KR20050074450A (https=)
CN (1) CN100372535C (https=)
AT (1) ATE359789T1 (https=)
AU (1) AU2003299065B2 (https=)
BR (1) BR0314647A (https=)
CA (1) CA2499738A1 (https=)
CR (1) CR7754A (https=)
DE (1) DE60313344T2 (https=)
EC (1) ECSP055700A (https=)
ES (1) ES2285251T3 (https=)
HR (1) HRP20050281A2 (https=)
MX (1) MXPA05003161A (https=)
NO (1) NO20051936L (https=)
PL (1) PL374696A1 (https=)
PT (1) PT1545534E (https=)
RS (1) RS20050228A (https=)
RU (1) RU2353364C2 (https=)
WO (1) WO2004028542A1 (https=)
ZA (1) ZA200502212B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519366A (ja) * 1997-10-15 2001-10-23 ポーラクス バイオファーマシュティカルズ，インコーポレーテッド ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
JP5027369B2 (ja) * 1999-12-06 2012-09-19 ガイストリッヒ ファーマ アーゲー 腫瘍を治療する方法

Also Published As

Publication number Publication date
NO20051936L (no) 2005-06-23
WO2004028542A1 (en) 2004-04-08
AU2003299065A1 (en) 2004-04-19
DE60313344T2 (de) 2008-01-03
MXPA05003161A (es) 2005-09-12
HRP20050281A2 (en) 2006-07-31
RU2353364C2 (ru) 2009-04-27
RS20050228A (sr) 2007-08-03
US20060128716A1 (en) 2006-06-15
ATE359789T1 (de) 2007-05-15
EP1545534B1 (en) 2007-04-18
CA2499738A1 (en) 2004-04-08
ES2285251T3 (es) 2007-11-16
CR7754A (es) 2005-12-02
RU2005112711A (ru) 2006-02-27
ECSP055700A (es) 2005-08-11
BR0314647A (pt) 2005-08-02
PT1545534E (pt) 2007-06-22
DE60313344D1 (de) 2007-05-31
ZA200502212B (en) 2006-02-22
CN1684684A (zh) 2005-10-19
JP2006502195A (ja) 2006-01-19
PL374696A1 (en) 2005-10-31
EP1545534A1 (en) 2005-06-29
CN100372535C (zh) 2008-03-05
AU2003299065B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
EA008056B1 (ru) Противораковые комбинации
JP2024546584A (ja) Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ
RU2353364C2 (ru) Применение производных 4-пиридилметилфталазина в производстве лекарственного средства для лечения миелодиспластических синдромов
KR20220124739A (ko) 암의 치료를 위한 병용 요법
EP3609471B1 (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
US11382877B2 (en) Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US20090233939A1 (en) Treatment of amm
US12156856B2 (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
RU2773153C1 (ru) Способ повышения уровня гемоглобина в крови у пациента, больного раком
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
EP4452275A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
HK40095413A (en) (e)-2,4,6-trimethoxystyryl-3- [(carboxymethyl)amino]-4- methoxybenzylsulphone, sodium salt for use in a method of treating a solid tumor cancer
HK40095413B (en) (e)-2,4,6-trimethoxystyryl-3- [(carboxymethyl)amino]-4- methoxybenzylsulphone, sodium salt for use in a method of treating a solid tumor cancer
JP2006502195A5 (https=)
HK40022425A (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
HK40022425B (en) Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050323

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080910

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100913

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100913

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I